Menu Search
Equities

Genmab A/S

GMABN:MEX

Genmab A/S

Actions
  • Price (MXN)5,019.82
  • Today's Change400.07 / 8.66%
  • Shares traded383.00
  • 1 Year change-12.06%
  • Beta--
Data delayed at least 20 minutes, as of Mar 27 2024 14:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

  • Revenue in DKK (TTM)19.76bn
  • Net income in DKK4.64bn
  • Incorporated1998
  • Employees2.64k
  • Location
    Genmab A/SCarl Jacobsens Vej 30VALBY 2500DenmarkDNK
  • Phone+45 70202728
  • Fax+45 70202729
  • Websitehttps://www.genmab.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GMAB:CPH since
announced		Transaction
value
ProfoundBio US CoAnnounced03 Apr 202403 Apr 2024Announced-27.23%1.80bn
Data delayed at least 15 minutes, as of Nov 14 2024 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.